The Committee identified a number of sections of the Model List that it considered to be in need of systematic review. These are listed in Table 4, together with an indication of the level of priority of the review.
Table 4
Sections of the Model List recommended for review, with level of priority
Section number |
Title |
Priority (notes) |
1 |
Anaesthetics (including muscle relaxants and preoperative medication) |
High |
2.4 |
Disease-modifying agents used in rheumatoid disorders |
Low |
3 |
Antiallergics and medicines used in anaphylaxis |
Low |
6.2.1 |
Cefalosporins |
High |
6.3 |
Antifungal medicines |
High |
7.2 |
Antimigraine medicines (prophylaxis) |
Low |
8 |
Antineoplastics, immuno-suppressives and medicines used in palliative care |
High |
11.1 |
Plasma substitutes |
High |
11.2 |
Plasma fractions for specific uses |
High |
12.2 |
Antiarrhythmic medicines |
High |
13 |
Dermatological medicines |
Medium |
14 |
Diagnostic agents |
Medium |
15 |
Disinfectants and antiseptics |
Low |
17.6 |
Laxatives |
Low |
20 |
Muscle relaxants (peripherally-acting) and cholinesterase inhibitors) |
With anaesthetics |
21 |
Ophthalmological preparations |
High |
25.1 |
Antiasthmatic medicines |
High |
26 |
Solutions correcting water, electrolyte and acid-base disturbances (intravenous solutions) |
Medium |
The Committee also recommended that a special review be carried out on the use of medicines in paediatrics.
The following medicines were identified as possible candidates for deletion according to the fast-track procedure at the next meeting of the Committee in 2004:
- ether (review actual consumption) (section 1.1 General anaesthetics and oxygen);
- colchicine (section 2.3 Medicines used to treat gout);
- clonazepam (section 5 Anticonvulsants/antiepileptics);
- niclosamide (section 6.1.1 Intestinal anthelminthics);
- pyrantel (section 6.1.1 Intestinal anthelminthics);
- triclabendazole (section 6.1.3 Antischistosomals and other antitrematode medicines);
- oxamniquine (section 6.1.3 Antischistosomals and other antitrematode medicines);
- imipenem + cilastatin (section 6.2.1 b-Lactam medicines);
- nalidixic acid (section 6.2.2 Other antibacterials);
- spectinomycin (section 6.2.2 Other antibacterials);
- levofloxacin (section 6.2.4 Antituberculosis medicines);
- thioacetazone + isoniazid (section 6.2.4 Antituberculosis medicines);
- diethyltoluamide (section 6.6 Insect repellents);
- ergotamine (section 7.1 Antimigraine medicines for treatment of acute attack);
- polygeline (section 11.1 Plasma substitutes);
- factor VIII and factor IX concentrates (section 11.2 Plasma fractions for specific uses);
- isoprenaline (section 12.2 Antiarrhythmic medicines);
- procainamide (section 12.2 Antiarrhythmic medicines);
- quinidine (section 12.2 Antiarrhythmic medicines);
- nifedepine (section 12.3 Antihypertensive medicines);
- topical sun protection agent (section 13.7 Ultraviolet-blocking agent);
- local anaesthetic, astringent and anti-inflammatory preparations (section 17.3 Antihaemorrhoidal medicines);
- atropine (in section 17.5 Antispasmodic medicines);
- codeine (in section 17.7.2 Antidiarrhoeal medicines (symptomatic) medicines);
- medroxyprogesterone acetate (in section 18.3.1 Hormonal contraceptives and section 18.7 Progestogens);
- silver nitrate (section 21.1 Anti-infective agents - Ophthalmological preparations);
- ergometrine (section 22.1 Oxytocics);
- salbutamol (in section 22.2 Antioxytocics);
- aminophylline (section 25.1 Antiasthmatic medicines);
- cromoglicic acid (section 25.1 Antiasthmatic medicines);
- theophylline (section 25.1 Antiasthmatic medicines);
- calcium gluconate (in section 27 Vitamins and minerals);
- sodium fluoride (section 27 Vitamins and minerals).
The Committee recommended that these items be identified in the present revision of the Model List with the following footnote:
The public health relevance and/or efficacy and/or safety of this item or group has been questioned and its continued inclusion in the Model List will be reviewed at the next meeting of the Expert Committee.
Cargando...
